Xeljanz and Effusion - a phase IV clinical study of FDA data
Summary:
Effusion is reported as a side effect among people who take Xeljanz (tofacitinib citrate), especially for people who are female, 50-59 old, have been taking the drug for 1 - 2 years also take Arava, and have Diarrhea.
The phase IV clinical study analyzes which people have Effusion when taking Xeljanz. It is created by eHealthMe based on reports of 238,928 people who have side effects when taking Xeljanz from the FDA, and is updated regularly.
What is Xeljanz?
Xeljanz has active ingredients of tofacitinib citrate. It is often used in rheumatoid arthritis. eHealthMe is studying from 239,081 Xeljanz users. Check the latest studies of Xeljanz.
What is Effusion?
Effusion (an escape of fluid into a body cavity) is found to be associated with 321 drugs and 437 conditions by eHealthMe. Check the latest studies of Effusion.
238,928 people reported to have side effects when taking Xeljanz.
Among them, 24 people (0.01%) have Effusion.

Among these 24 people:
How long have people been on Xeljanz when they have Effusion? *
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 100 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Effusion when taking Xeljanz? *
- female: 83.33 %
- male: 16.67 %
What is the age of people who have Effusion when taking Xeljanz? *
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 27.27 %
- 40-49: 0.0 %
- 50-59: 54.55 %
- 60+: 18.18 %
What are other drugs people take besides Xeljanz? *
- Arava: 8 people, 33.33%
- Enbrel: 6 people, 25.00%
- Humira: 6 people, 25.00%
- Dexilant: 5 people, 20.83%
- Vitamin B12: 5 people, 20.83%
- Tylenol: 5 people, 20.83%
- Rivaroxaban: 5 people, 20.83%
- Plaquenil: 5 people, 20.83%
- Micardis: 5 people, 20.83%
- Xarelto: 4 people, 16.67%
What are other side effects people have besides Effusion? *
- Joint Pain: 17 people, 70.83%
- Joint Swelling: 9 people, 37.50%
- Pain: 9 people, 37.50%
- Synovitis (inflammation of the synovial membrane): 8 people, 33.33%
- Joint Stiffness: 8 people, 33.33%
- Swelling: 8 people, 33.33%
- Drug Ineffective: 8 people, 33.33%
- Back Pain: 6 people, 25.00%
- High Blood Pressure: 6 people, 25.00%
- Arthritis (form of joint disorder that involves inflammation of one or more joints): 6 people, 25.00%
What are the existing conditions these people have? *
- Stress And Anxiety: 2 people, 8.33%
- Diarrhea: 2 people, 8.33%
- Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 1 person, 4.17%
* Approximation only. Some reports may have incomplete information.
Do you take Xeljanz and have Effusion?
- Check whether Effusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Xeljanz:
- Xeljanz (239,081 reports)
Effusion treatments and more:
- Effusion (1,833 reports)
How severe was Effusion and when was it recovered:
Expand to all the drugs that have ingredients of tofacitinib citrate:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Xeljanz:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Effusion:
- Effusion (321 drugs)
Browse all the conditions that are associated with Effusion:
- Effusion (437 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz) and Xeljanz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Alendronic Acid cause Progressive Multifocal Leukoencephalopathy? - now
- Could Paxil Cr cause Death? - 7 seconds ago
- Could Oncovin cause Speech Impairment (Adult)? - 9 seconds ago
- Drug interactions of Crixivan and Gabapentin - 13 seconds ago
- Could Meticorten cause Rheumatoid Arthritis? - 14 seconds ago
- Could Advair Hfa cause Hair Disorder? - 15 seconds ago
- Could Advair Diskus 100/50 cause Rash Maculo-Papular? - 18 seconds ago
- Could Lasix cause Chest Pain? - 22 seconds ago
- Could Dasatinib cause Back Pain? - 26 seconds ago
- Drug interactions of Robitussin and Avelox - 27 seconds ago